Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer

References

• Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr. Treat. Options. Oncol. 13(3), 377–389 (2012).
   PubMed Web of Science ®Google Scholar
• De Vita F, Giuliani F, Silvestris N et al. Current status of targeted therapies in advanced gastric cancer. Expert. Opin. Ther. Targets 16( Suppl. 16), S29–S34 (2012).
   PubMed Web of Science ®Google Scholar
• Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N. Molecular pathology of gastric cancer: research and practice. Pathol. Res. Pract. 207(10), 608–612 (2011).
   PubMedGoogle Scholar
• Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics. Int. J. Mol. Med. 23(3), 307–311 (2009).
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. FGF signaling network in the gastrointestinal tract. Int. J. Oncol. 29(1), 163–168 (2006).
   PubMedGoogle Scholar
• Kumar SB, Narasu L, Gundla R, Dayam R, J A R P S. Fibroblast growth factor receptor inhibitors. Curr. Pharm. Des. 19(4), 687–701 (2013).
   PubMedGoogle Scholar
• Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin. Cancer Res. 18(7), 1855–1862 (2012).
   PubMed Web of Science ®Google Scholar
• Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. doi:10.1002/med.21288 (2013) ( Epub ahead of print).
   PubMedGoogle Scholar
• Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int. J. Oncol. 33(2), 233–237 (2008).
   PubMed Web of Science ®Google Scholar
• Katoh M. FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J. Invest. Dermatol. 129(8), 1861–1867 (2009).
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. Recombination cluster around FGFR2-WDR11-HTPAPL locus on human chromosome 10q26. Int. J. Mol. Med. 11(5), 579–583 (2003).
   PubMedGoogle Scholar
• Xu R, Rudd TR, Hughes AJ, Siligardi G, Fernig DG, Yates EA. Analysis of the fibroblast growth factor receptor (FGFR) signalling network with heparin as coreceptor: evidence for the expansion of the core FGFR signalling network. FEBS J. 280(10), 2260–2270 (2013).
   PubMedGoogle Scholar
• Christensen C, Berezin V, Bock E. Neural cell adhesion molecule differentially interacts with isoforms of the fibroblast growth factor receptor. Neuroreport 22(15), 727–732 (2011).
   PubMedGoogle Scholar
• Yamashita K, Sakuramoto S, Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg. Today 41(1), 24–38 (2011).
   PubMedGoogle Scholar
• Guo T, Fan L, Ng WH et al. Multidimensional Identification of Tissue Biomarkers of Gastric Cancer. J Proteome Res. (2012) ( Epub ahead of print).
   Google Scholar
• Matsumoto K, Arao T, Hamaguchi T et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br. J. Cancer. 106(4), 727–732 (2012).
   PubMed Web of Science ®Google Scholar
• Kim HK, Choi IJ, Kim CG et al. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J. 12(2), 119–127 (2012).
   PubMed Web of Science ®Google Scholar
• Hattori Y, Itoh H, Uchino S, Hosokawa Ket al. Immunohistochemical detection ofK-sam protein in stomach cancer. Clin. Cancer Res. 2(8), 1373–1381 (1996).
   PubMed Web of Science ®Google Scholar
• Toyokawa T, Yashiro M, Hirakawa K. Co-expression of keratinocyte growthfactor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol. Rep. 21(4), 875–880(2009).
   PubMedGoogle Scholar
• Katoh M. Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev. Anticancer Ther. 10(9), 1375–1379 (2010).
   PubMed Web of Science ®Google Scholar
• Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol. Ther. 6(6), 832–839 (2007).
   PubMed Web of Science ®Google Scholar
• Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61(9), 3541–3543 (2001).
   PubMed Web of Science ®Google Scholar
• Kunii K, Davis L, Gorenstein J et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68(7), 2340–2348 (2008).
   PubMed Web of Science ®Google Scholar
• Park S, Kim JH, Jang JH. Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines. Biochem. Biophys. Res. Commun. 357(4), 1011–1015 (2007).
   PubMedGoogle Scholar
• Takeda M, Arao T, Yokote H et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin. Cancer Res. 13(10), 3051–3057 (2007).
   PubMed Web of Science ®Google Scholar
• Xie L, Su X, Zhang L et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19(9), 2572–2583 (2013).
   PubMed Web of Science ®Google Scholar
• Burbridge MF, Bossard CJ, Saunier C et al. S49076 is a novel kinase inhibitor of MET, AXL and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol. Cancer Ther. (2013) ( Epub ahead of print).
   PubMedGoogle Scholar
• Bai A, Meetze K, Vo NY et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 70(19), 7630–7639 (2010).
   PubMed Web of Science ®Google Scholar
• Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin. Exp. Metastasis. 14(1), 43–54 (1996).
   PubMedGoogle Scholar
• Nakamura K, Yashiro M, Matsuoka T et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131(5), 1530–1541 (2006).
   PubMedGoogle Scholar
• Kataoka Y, Mukohara T, Tomioka H et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest. New Drugs 30(4), 1352–1360 (2012).
   PubMed Web of Science ®Google Scholar
• Pan BS, Chan GK, Chenard M et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 70(4), 1524–1533 (2010).
   PubMedGoogle Scholar
• Garrett CR, Siu LL, El-Khoueiry A et al. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br. J. Cancer 105(1), 44–52 (2011).
   PubMed Web of Science ®Google Scholar
• Park JW, Finn RS, Kim JS et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 17(7), 1973–83 (2011).
   PubMed Web of Science ®Google Scholar
• Gozgit JM, Wong MJ, Moran L et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11(3), 690–699 (2012).
   PubMed Web of Science ®Google Scholar
• Gozgit JM, Squillace RM, Wongchenko MJ et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother. Pharmacol. 71(5), 1315–1323 (2013).
   PubMed Web of Science ®Google Scholar
• Zhao G, Li WY, Chen D et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther. 10(11), 2200–2210 (2012).
   Google Scholar
• Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 6(4), 527–537 (2010).
   PubMedGoogle Scholar
• Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 75(9), 831–842 (2007).
   PubMedGoogle Scholar
• Qiu H, Yashiro M, Zhang X, Miwa A, Hirakawa K. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Lett. 307(1), 47–52 (2011).
   PubMed Web of Science ®Google Scholar
• Yashiro M, Shinto O, Nakamura K et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int. J. Cancer 126(4), 1004–1016 (2010).
   PubMed Web of Science ®Google Scholar
• Asaoka Y, Ikenoue T, Koike K. New targeted therapies for gastric cancer. Expert Opin. Investig. Drugs 20(5), 595–604 (2011).
   PubMed Web of Science ®Google Scholar
• Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61(5), 673–684 (2012).
   PubMed Web of Science ®Google Scholar
• Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem. 45(7), 1005–1019 (1997).
   PubMed Web of Science ®Google Scholar
• La Rosa S, Uccella S, Erba S et al. Immunohistochemical detection of fibroblast growth factor receptors in normal endocrine cells and related tumors of the digestive system. Appl. Immunohistochem. Mol. Morphol. 9(4), 319–328 (2001).
   PubMedGoogle Scholar
• Katoh M, Katoh M. FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Int. J. Oncol. 22(5), 1155–1159 (2003).
   PubMedGoogle Scholar